NICE recommends Cabometyx (cabozantinib) to treat renal cell carcinoma.- Ipsen.
The National Institute for Health and Care Excellence ( NICE) has published final guidance and reversed an earlier negative decision to recommend Cabometyx (cabozantinib) from Ipsen for use in adults after VEGF targeted therapy to treat renal cell carcinoma.
The drug showed an incremental cost effectiveness ratio of more than �60 000 per QALY gained compared to Afinitor (everolimus ) from Novartis, and NICE was offered a confidential patient access scheme persuading it that the drug was cost effective in a field where there are limited treatment options.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.